Merck & Co. has joined a research deal with generic-drug maker Ranbaxy Laboratories to develop treatments for bacterial and fungal infections. Under the terms of the deal, which could reach more than $100 million, Ranbaxy will be responsible for early-stage development of treatments while Merck will handle late-stage clinical trials.

Related Summaries